Benefit of nectin-4 targeting with enfortumab vedotin confirmed

Nat Rev Urol. 2021 Apr;18(4):190. doi: 10.1038/s41585-021-00449-1.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal*
  • Cell Adhesion Molecules / genetics
  • Humans
  • Nectins
  • Urologic Neoplasms*

Substances

  • Antibodies, Monoclonal
  • Cell Adhesion Molecules
  • Nectins
  • enfortumab vedotin